BioCryst Pharmaceuticals (BCRX) Short Interest Ratio & Short Volume → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free BCRX Stock Alerts $6.28 -0.19 (-2.94%) (As of 05/17/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability BioCryst Pharmaceuticals Short Interest DataCurrent Short Volume33,640,000 sharesPrevious Short Volume34,390,000 sharesChange Vs. Previous Month-2.18%Dollar Volume Sold Short$138.93 millionShort Interest Ratio / Days to Cover9.9Last Record DateApril 30, 2024Outstanding Shares206,380,000 sharesPercentage of Shares Shorted16.30%Today's Trading Volume4,378,855 sharesAverage Trading Volume4,236,906 sharesToday's Volume Vs. Average103% Short Selling BioCryst Pharmaceuticals ? Sign up to receive the latest short interest report for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatBCRX Short Interest Over TimeBCRX Days to Cover Over TimeBCRX Percentage of Float Shorted Over Time Ad Porter & CompanyObama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here BioCryst Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202433,640,000 shares $138.93 million -2.2%N/A9.9 $4.13 4/15/202434,390,000 shares $160.60 million +6.6%N/A11 $4.67 3/31/202432,250,000 shares $163.83 million +5.6%N/A9.8 $5.08 3/15/202430,550,000 shares $152.75 million +5.0%N/A9.3 $5.00 2/29/202429,100,000 shares $163.83 million -1.1%N/A7.4 $5.63 2/15/202429,410,000 shares $165.87 million +1.3%N/A7.6 $5.64 Get the Latest News and Ratings for BCRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/202429,040,000 shares $153.91 million +3.5%N/A7.6 $5.30 1/15/202428,050,000 shares $178.12 million -6.8%N/A7.1 $6.35 12/31/202330,080,000 shares $180.18 million +1.0%N/A7.4 $5.99 12/15/202329,780,000 shares $184.34 million +1.4%N/A7.8 $6.19 11/30/202329,380,000 shares $172.75 million -0.3%N/A8.5 $5.88 11/15/202329,470,000 shares $153.54 million -2.2%N/A10.3 $5.21 10/31/202330,130,000 shares $165.41 million -31.8%N/A10.9 $5.49 10/15/202344,190,000 shares $262.49 million +4.3%N/A15.5 $5.94 9/30/202342,390,000 shares $300.12 million -0.3%N/A17 $7.08 9/15/202342,500,000 shares $291.13 million +2.9%N/A16.9 $6.85 8/31/202341,300,000 shares $293.64 million +3.1%N/A16.3 $7.11 8/15/202340,060,000 shares $278.02 million +2.7%N/A15.2 $6.94 7/31/202339,000,000 shares $288.21 million +3.4%N/A14.7 $7.39 7/15/202337,730,000 shares $269.01 million +0.9%N/A14.9 $7.13 6/30/202337,390,000 shares $263.23 million +5.4%N/A13.8 $7.04 6/15/202335,480,000 shares $283.13 million -0.3%N/A12.9 $7.98 5/31/202335,580,000 shares $294.25 million +10.2%N/A13 $8.27 5/15/202332,300,000 shares $283.27 million +3.5%N/A11 $8.77 4/30/202331,200,000 shares $237.43 million +2.8%N/A10.2 $7.61 4/15/202330,360,000 shares $245.01 million -2.8%N/A10.5 $8.07 3/31/202331,220,000 shares $260.37 million +1.3%N/A10.7 $8.34 3/15/202330,810,000 shares $257.88 million +4.5%N/A10.3 $8.37 2/28/202329,480,000 shares $260.90 million +9.2%N/A9.9 $8.85 2/15/202326,990,000 shares $274.22 million +1.2%N/A9.7 $10.16 1/31/202326,680,000 shares $281.47 million +2.2%N/A10.2 $10.55 1/15/202326,110,000 shares $265.28 million -4.2%N/A8.8 $10.16 12/30/202227,240,000 shares $312.72 million -1.6%N/A9.6 $11.48 12/15/202227,680,000 shares $299.22 million +0.3%N/A10.3 $10.81 11/30/202227,610,000 shares $368.87 million -0.9%N/A10.3 $13.36 11/15/202227,870,000 shares $369.00 million +0.9%N/A10.7 $13.24 10/31/202227,630,000 shares $368.86 million -2.3%N/A10.5 $13.35 10/15/202228,290,000 shares $382.76 million +0.6%N/A11 $13.53 9/30/202228,130,000 shares $354.44 million -2.4%N/A10.9 $12.60 9/15/202228,820,000 shares $369.76 million +3.3%N/A10.5 $12.83Obama’s Forever Term [exposed] (Ad)America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.Start streaming it now at no cost here BCRX Short Interest - Frequently Asked Questions What is BioCryst Pharmaceuticals' current short interest? Short interest is the volume of BioCryst Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 30th, traders have sold 33,640,000 shares of BCRX short. Learn More on BioCryst Pharmaceuticals' current short interest. What is a good short interest ratio for BioCryst Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BCRX shares currently have a short interest ratio of 10.0. Learn More on BioCryst Pharmaceuticals's short interest ratio. Which institutional investors are shorting BioCryst Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of BioCryst Pharmaceuticals: Walleye Trading LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is BioCryst Pharmaceuticals' short interest increasing or decreasing? BioCryst Pharmaceuticals saw a decline in short interest during the month of April. As of April 30th, there was short interest totaling 33,640,000 shares, a decline of 2.2% from the previous total of 34,390,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does BioCryst Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to BioCryst Pharmaceuticals: Novavax, Inc. (32.00%), Scholar Rock Holding Co. (16.78%), Cullinan Oncology, Inc. (10.23%), Autolus Therapeutics plc (1.32%), Immatics (10.50%), ProKidney Corp. (22.89%), 4D Molecular Therapeutics, Inc. (18.61%), Relay Therapeutics, Inc. (8.69%), Vir Biotechnology, Inc. (6.63%), Mesoblast Limited (0.79%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short BioCryst Pharmaceuticals stock? Short selling BCRX is an investing strategy that aims to generate trading profit from BioCryst Pharmaceuticals as its price is falling. BCRX shares are trading down $0.19 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against BioCryst Pharmaceuticals? A short squeeze for BioCryst Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of BCRX, which in turn drives the price of the stock up even further. How often is BioCryst Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BCRX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: NVAX Short Interest SRRK Short Interest CGEM Short Interest AUTL Short Interest IMTX Short Interest PROK Short Interest FDMT Short Interest RLAY Short Interest VIR Short Interest MESO Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:BCRX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport SocietyCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings